Trevi Therapeutics

General Information


We are a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. We are currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.

Employees: 16
Founded: 2011
Contact Information
Address 195 Church Street, 14th Floor, New Haven, CT 06510, US
Phone Number (203) 304-2499
Web Address
View Prospectus: Trevi Therapeutics
Financial Information
Market Cap $177.7mil
Revenues $0 mil (last 12 months)
Net Income $-25.6 mil (last 12 months)
IPO Profile
Symbol TRVI
Exchange NASDAQ
Shares (millions): 5.5
Price range $10.00 - $10.00
Est. $ Volume $55.0 mil
Manager / Joint Managers SVB Leerink/ Stifel/ BMO Capital Markets
CO-Managers Needham & Co.
Expected To Trade: 5/7/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change